Glioblastoma Clinical Trials in Phoenix, AZ

View the best 10 glioblastoma medical studies in Phoenix, Arizona. Access promising new therapies by applying to a Phoenix-based Glioblastoma clinical trial.

Trials in Phoenix, Arizona

Here are the top 9 medical studies for glioblastoma in Phoenix, Arizona

Niraparib

PARP Inhibitor

Recruiting2 awardsPhase 3

"This trial will compare two drugs, niraparib and temozolomide, to see which one is more effective for treating a specific type of brain cancer called glioblastoma. The

Temsirolimus

mTOR Inhibitor

Recruiting1 awardPhase < 1

This trial tests if a drug can treat recurrent high-grade brain tumors. Patients receive an infusion of the drug on the day of surgery.

Radiation Therapy

Radiation

Recruiting1 awardPhase 2

This trial studies how well dabrafenib and trametinib work after radiation therapy in children and young adults with a specific type of brain tumor. These drugs help stop tumor growth by blocking signals that tell the cells to multiply. Dabrafenib has been developed and tested extensively for a specific type of skin cancer, showing effectiveness both alone and when used with trametinib.

GammaTile radiation therapy implantation +3 More

Brachytherapy

Recruiting3 awardsPhase 4

This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.

Retifanlimab

Monoclonal Antibodies

Recruiting1 awardPhase 2

This trial tests if retifanlimab + bevacizumab + radiation can improve treatment of recurrent glioblastoma. Protein and drugs may help immune system fight cancer & stop blood vessels supplying tumor.

Selinexor +1 More

Selective Inhibitor of Nuclear Export

Recruiting1 awardPhase 1 & 2

This trial tests selinexor with temozolomide for patients whose brain cancer has returned. Selinexor blocks a protein that helps cancer cells grow, and temozolomide damages their DNA to kill them or stop their growth. Temozolomide is a DNA methylating drug currently used as a first-line treatment in glioblastoma therapy.

BDTX-1535

Small Molecule Inhibitor

Recruiting1 awardPhase 1 & 2

This trial is testing a new drug for people with glioblastoma or non-small cell lung cancer who have disease progression following standard of care.

WSD0922-FU

EGFR/EGFRvIII Inhibitor

Recruiting1 awardPhase 1

This trial is testing a new drug called WSD0922-FU for patients with aggressive brain and spinal cord cancers. The drug works by blocking a protein that helps cancer cells grow. The goal is to find the best dose and see if it can effectively treat these hard-to-treat cancers.

APL-101

Small Molecule Inhibitor

Recruiting1 awardPhase 2

This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.

Popular Filters

Trials With No Placebo

PARP Inhibitor

Niraparib vs Temozolomide for Brain Cancer

Recruiting2 awardsPhase 3

Phoenix, Arizona

"This trial will compare two drugs, niraparib and temozolomide, to see which one is more effective for treating a specific type of brain cancer called glioblastoma. The

mTOR Inhibitor

Temsirolimus Infusion for Brain Tumor

Recruiting1 awardPhase < 1

Phoenix, Arizona

This trial tests if a drug can treat recurrent high-grade brain tumors. Patients receive an infusion of the drug on the day of surgery.

Brachytherapy

GammaTile + Stupp Protocol for Glioblastoma

Recruiting3 awardsPhase 4

Scottsdale, Arizona

This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.

Small Molecule Inhibitor

BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

Recruiting1 awardPhase 1 & 2

Gilbert, Arizona

This trial is testing a new drug for people with glioblastoma or non-small cell lung cancer who have disease progression following standard of care.

ATM Kinase Inhibitor

AZD1390 for Glioblastoma

Recruiting1 awardPhase < 1

Phoenix, Arizona

This trial tests a new drug, AZD1390, combined with radiation therapy in patients with severe brain cancer. AZD1390 is designed to enhance the effectiveness of radiation in killing cancer cells.

Chemotherapy

NMS-03305293 + Temozolomide for Glioblastoma

Recruiting1 awardPhase 1 & 2

Phoenix, Arizona

This trial is testing a new combination of drugs to treat adults with gliomas, with the goal of finding a safe and effective treatment.

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.